Press releases

Positive results from Harmony Outcomes study of albiglutide published in The Lancet

GSK and the Duke Clinical Research Institute (DCRI) today announced publication of positive results from the Harmony Outcomes study which assessed the cardiovascular (CV) safety and efficacy of albiglutide, a GLP-1 receptor agonist, in patients with type 2 diabetes and cardiovascular disease. Results were presented at the European Association for the Study of Diabetes congress 2018 with simultaneous publication in The Lancet.[i]

Read more - Positive results from Harmony Outcomes study of albiglutide published in The Lancet Read more